Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CO NYSE:CORBF NASDAQ:MRAI NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$0.71+29.1%$1.02$2.03▼$5.50$86.30M0.16216,519 shs660 shsCORBFGlobal Cord Blood$0.71+29.1%$1.00$0.25▼$2.00$86.30M-0.52105,408 shs660 shsMRAIMarpai$1.31-2.2%$1.33$0.40▼$1.68$21.66M4.6817,158 shs2,834 shsSCPHscPharmaceuticals$5.60-4.1%$4.11$1.94▼$6.28$295.64M0.38330,019 shs497,056 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood0.00%-26.67%-63.33%-47.62%-59.26%CORBFGlobal Cord Blood+29.09%+29.09%-52.67%-32.38%-52.98%MRAIMarpai-2.24%+2.34%+3.15%+31.00%+111.31%SCPHscPharmaceuticals-4.11%+13.36%+41.06%+123.11%+15.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals4.3758 of 5 stars3.54.00.04.22.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGlobal Cord Blood 0.00N/AN/AN/ACORBFGlobal Cord Blood 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ASCPHscPharmaceuticals 3.00Buy$14.00150.00% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGlobal Cord Blood$1.24B0.07$0.17 per share4.19$6.34 per share0.11CORBFGlobal Cord Blood$196.12M0.44$0.51 per share1.40N/A∞MRAIMarpai$34.87M0.62N/AN/A($1.72) per share-0.76SCPHscPharmaceuticals$36.33M8.14N/AN/A$0.27 per share20.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGlobal Cord Blood$79.04M$0.641.11∞N/AN/AN/AN/AN/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/7/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)Latest CO, CORBF, MRAI, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCPHscPharmaceuticals-$0.30N/AN/AN/A$15.41 millionN/A5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGlobal Cord Blood$0.0811.27%N/A12.50%N/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGlobal Cord BloodN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AMRAIMarpaiN/A0.820.82SCPHscPharmaceuticals3.865.484.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGlobal Cord BloodN/ACORBFGlobal Cord BloodN/AMRAIMarpai49.75%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipCOGlobal Cord Blood0.50%CORBFGlobal Cord Blood0.50%MRAIMarpai46.10%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableMRAIMarpai15016.54 million5.61 millionNo DataSCPHscPharmaceuticals3052.79 million50.27 millionOptionableCO, CORBF, MRAI, and SCPH HeadlinesRecent News About These CompaniesscPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?July 25 at 9:16 AM | zacks.comscPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Sold by AIGH Capital Management LLCJuly 22, 2025 | marketbeat.comRice Hall James & Associates LLC Boosts Stock Position in scPharmaceuticals, Inc. (NASDAQ:SCPH)July 14, 2025 | marketbeat.comWith 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interestJune 12, 2025 | finance.yahoo.comscPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025May 22, 2025 | seekingalpha.comscPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 16, 2025 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comAQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comAscPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comscPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comInsights Ahead: scPharmaceuticals's Quarterly EarningsMay 13, 2025 | benzinga.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 5.24%May 7, 2025 | aaii.comAscPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025May 7, 2025 | globenewswire.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 5.85%May 6, 2025 | aaii.comAscPharmaceuticals Announces Participation in Three Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the StartWhy Wall Street Is Betting on These 3 Comeback StocksBy Nathan Reiff | July 12, 2025View Why Wall Street Is Betting on These 3 Comeback StocksCO, CORBF, MRAI, and SCPH Company DescriptionsGlobal Cord Blood NYSE:CO$0.71 +0.16 (+29.09%) As of 07/25/2025Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Global Cord Blood NYSE:CORBF$0.71 +0.16 (+29.09%) As of 07/25/2025 03:49 PM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Marpai NASDAQ:MRAI$1.31 -0.03 (-2.24%) As of 07/25/2025 03:57 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.scPharmaceuticals NASDAQ:SCPH$5.60 -0.24 (-4.11%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.70 +0.10 (+1.70%) As of 07/25/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
